Form 8-K - Current report:
SEC Accession No. 0001193125-25-076938
Filing Date
2025-04-09
Accepted
2025-04-09 17:26:23
Documents
16
Period of Report
2025-04-08
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d906762d8k.htm   iXBRL 8-K 31656
2 EX-99.1 d906762dex991.htm EX-99.1 22476
7 GRAPHIC g906762g0410012356627.jpg GRAPHIC 4444
  Complete submission text file 0001193125-25-076938.txt   227730

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tpst-20250408.xsd EX-101.SCH 3883
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tpst-20250408_def.xml EX-101.DEF 13698
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20250408_lab.xml EX-101.LAB 22682
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20250408_pre.xml EX-101.PRE 14666
19 EXTRACTED XBRL INSTANCE DOCUMENT d906762d8k_htm.xml XML 5520
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 25825992
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)